RTI Surgical Announces First Patient Enrolled in Investigational Device Exemption (IDE) for Cortiva® Allograft Dermis in Breast Reconstruction

UF Startup RTI Surgical, a leading CDMO pushing the boundaries of innovation and tissue engineering to address patient needs in regenerative medicine, announced the enrollment of the first patient in ADMIRE (Acellular Dermal Matrix Investigation in Breast Reconstruction). This Investigational Device Exemption study is designed to confirm the safety and effectiveness of Cortiva® Allograft Dermis (ADM) in implant-based breast reconstruction.